Prognostic markers in colorectal pathology: Is morphology enough?

Diagnostic Histopathology

Volumn 17, Issue 9, 2011, Pages 386-394

  Wang, Lai Mun ^a   Sheahan, Kieran ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Biomarkers; Colorectal cancer; Morphology; Prognostic markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SCREENING; CANCER STAGING; CELL DIFFERENTIATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH VESSEL; LYMPHADENECTOMY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVERALL SURVIVAL; PERITONEAL CAVITY; POINT MUTATION; STRATIFICATION; TUMOR PERFORATION;

EID: 80051863620     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2011.06.016     Document Type: Article

References (71)

1. Cunningham D., Atkin W., Lenz H.J., et al. Colorectal cancer. Lancet 2010 Mar 20, 375:1030-1047.
2. He Y.D., Friend S.H. Microarrays - the 21st century divining rod?. Nat Med 2001 Jun, 7:658-659.
3. Foucar E. Classification in anatomic pathology. Am J Clin Pathol 2001 Dec, 116(suppl):S5-S20.
4. Gospodarowicz M., O'Sullivan B. Prognostic factors in cancer. Semin Surg Oncol 2003, 21:13-18.
5. Gospodarowicz M., Mackillop W., O'Sullivan B., et al. Prognostic factors in clinical decision making: the future. Cancer 2001 Apr 15, 91(8 suppl):1688-1695.
6. Gospodarowicz M., Henson D., Hutter R., O'Sullivan B., Sobin L., Wittekind C. Prognostic factors in cancer 2001, Wiley-Liss, New York. 2nd edn.
7. Puppa G., Sonzogni A., Colombari R., Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med 2010 Jun, 134:837-852.
8. Puppa G. TNM staging system of colorectal carcinoma: surgical pathology. Diagn Histopathol 2011 Jun, 17:243-262.
9. Kyriakos M. The President's cancer, the Dukes classification, and confusion. Arch Pathol Lab Med 1985 Dec, 109:1063-1066.
10. Quirke P., Risio M., Lambert R., von Karsa L., Vieth M. Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch 2011 Jan, 458:1-19.
11. Gospodarowicz M.K., Miller D., Groome P.A., Greene F.L., Logan P.A., Sobin L.H. The process for continuous improvement of the TNM classification. Cancer 2004 Jan 1, 100:1-5.
12. International Union Against Cancer. TNM classification of malignant tumours 1997, Wiley-Liss, New York. 5th edn. L. Sobin, C. Wittekind (Eds.).
13. AJCC cancer staging manual 1997, Lipincott-Raven, Philadelphia. 5th edn. I. Fleming, J. Cooper, D. Hensen (Eds.).
14. International Union against cancer. TNM classification of malignant tumours 2009, Wiley-Blackwell. L. Sobin, M. Gospodarowicz, C. Wittekind (Eds.).
15. AJCC cancer staging manual 2010, Springer. S. Edge, D. Byrd, C. Compton, A. Fritz, F. Greene, A. Trotti (Eds.).
16. Greene F.L. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol 2003, 21:23-29.
17. The Royal College of Pathologists Standards and datasets for reporting cancers. Dataset for colorectal cancer 2007, 2nd edn.
18. Bori R., Sejben I., Svebis M., et al. Heterogeneity of pT3 colorectal carcinomas according to the depth of invasion. Pathol Oncol Res 2009 Sep, 15:527-532.
19. Merkel S., Mansmann U., Siassi M., Papadopoulos T., Hohenberger W., Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001 Sep, 16:298-304.
20. Petersen V.C., Baxter K.J., Love S.B., Shepherd N.A. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002 Jul, 51:65-69.
21. Shepherd N.A., Baxter K.J., Love S.B. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997 Apr, 112:1096-1102.
22. Lennon A.M., Mulcahy H.E., Hyland J.M., et al. Peritoneal involvement in stage II colon cancer. Am J Clin Pathol 2003 Jan, 119:108-113.
23. Kojima M., Nakajima K., Ishii G., Saito N., Ochiai A. Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol 2010 Sep, 34:1351-1360.
24. Puppa G., Shepherd N.A., Sheahan K., Stewart C.J. Peritoneal elastic lamina invasion in colorectal cancer: the answer to a controversial area of pathology?. Am J Surg Pathol 2011 Mar, 35:465-468. author reply 8-9.
25. Colon & Rectum. American Joint Committee on Cancer AJCC cancer staging manual 2002, Springer, NY. 6th edn.
26. Rosenberg R., Engel J., Bruns C., et al. The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg 2010 Jun, 251:1070-1078.
27. Sarli L., Bader G., Iusco D., et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer 2005 Jan, 41:272-279.
28. Joseph N.E., Sigurdson E.R., Hanlon A.L., et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003 Apr, 10:213-218.
29. Prandi M., Lionetto R., Bini A., et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002 Apr, 235:458-463.
30. Chapuis P.H., Chan C., Dent O.F. Clinicopathological staging of colorectal cancer: evolution and consensus - an Australian perspective. J Gastroenterol Hepatol 2011 Jan, 26(suppl 1):58-64.
31. Rosenberg R., Friederichs J., Schuster T., et al. Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg 2008 Dec, 248:968-978.
32. Gray R., Barnwell J., McConkey C., Hills R.K., Williams N.S., Kerr D.J. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007 Dec 15, 370:2020-2029.
33. Benson A.B., Schrag D., Somerfield M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004 Aug 15, 22:3408-3419.
34. Compton C., Fenoglio-Preiser C.M., Pettigrew N., Fielding L.P. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000 Apr 1, 88:1739-1757.
35. Talbot I.C., Ritchie S., Leighton M.H., Hughes A.O., Bussey H.J., Morson B.C. Spread of rectal cancer within veins. Histologic features and clinical significance. Am J Surg 1981 Jan, 141:15-17.
36. Suzuki A., Togashi K., Nokubi M., et al. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol 2009 Nov, 33:1601-1607.
37. Littleford S.E., Baird A., Rotimi O., Verbeke C.S., Scott N. Interobserver variation in the reporting of local peritoneal involvement and extramural venous invasion in colonic cancer. Histopathology 2009 Oct, 55:407-413.
38. Harris E.I., Lewin D.N., Wang H.L., et al. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol 2008 Dec, 32:1816-1821.
39. Sternberg A., Mizrahi A., Amar M., Groisman G. Detection of venous invasion in surgical specimens of colorectal carcinoma: the efficacy of various types of tissue blocks. J Clin Pathol 2006 Feb, 59:207-210.
40. Sato T., Ueno H., Mochizuki H., et al. Objective criteria for the grading of venous invasion in colorectal cancer. Am J Surg Pathol 2010 Apr, 34:454-462.
41. Liebig C., Ayala G., Wilks J., et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009 Nov 1, 27:5131-5137.
42. Poeschl E.M., Pollheimer M.J., Kornprat P., et al. Perineural invasion: correlation with aggressive phenotype and independent prognostic variable in both colon and rectum cancer. J Clin Oncol 2010 Jul 20, 28:e358-e360. author reply e61-2.
43. Liebig C., Ayala G., Wilks J.A., Berger D.H., Albo D. Perineural invasion in cancer: a review of the literature. Cancer 2009 Aug 1, 115:3379-3391.
44. Ceyhan G.O., Liebl F., Maak M., et al. The severity of neural invasion is a crucial prognostic factor in rectal cancer independent of neoadjuvant radiochemotherapy. Ann Surg 2010 Nov, 252:797-804.
45. Jass J.R., Love S.B., Northover J.M. A new prognostic classification of rectal cancer. Lancet 1987 Jun 6, 1:1303-1306.
46. Kurtz K.A., Hoffman H.T., Zimmerman M.B., Robinson R.A. Perineural and vascular invasion in oral cavity squamous carcinoma: increased incidence on re-review of slides and by using immunohistochemical enhancement. Arch Pathol Lab Med 2005 Mar, 129:354-359.
47. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007 Jan, 50:151-162.
48. Prall F., Nizze H., Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005 Jul, 47:17-24.
49. Tanaka M., Hashiguchi Y., Ueno H., Hase K., Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003 Aug, 46:1054-1059.
50. Wang L.M., Kevans D., Mulcahy H., et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009 Jan, 33:134-141.
51. European guidelines for quality assurance in colorectal cancer screening and diagnosis 2010, 1st edn. N. Segnan, J. Patnick, L. von Karsa (Eds.).
52. Ueno H., Mochizuki H., Hashiguchi Y., et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004 Aug, 127:385-394.
53. Masaki T., Matsuoka H., Sugiyama M., Abe N., Sakamoto A., Atomi Y. Actual number of tumor budding as a new tool for the individualization of treatment of T1 colorectal carcinomas. J Gastroenterol Hepatol 2006 Jul, 21:1115-1121.
54. Sakuragi M., Togashi K., Konishi F., et al. Predictive factors for lymph node metastasis in T1 stage colorectal carcinomas. Dis Colon Rectum 2003 Dec, 46:1626-1632.
55. Ward R.L., Turner J., Williams R., et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005 Dec, 207:377-384.
56. Hutchins G., Southward K., Handley K., et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011 Apr 1, 29:1261-1270.
57. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010 Jul 10, 28:3219-3226.
58. Roth A.D., Tejpar S., Delorenzi M., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010 Jan 20, 28:466-474.
59. Heinemann V., Stintzing S., Kirchner T., Boeck S., Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009 May, 35:262-271.
60. van Puijenbroek M., Nielsen M., Tops C.M., et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G > T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res 2008 Jan 1, 14:139-142.
61. Banck M.S., Grothey A. Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res 2009 Dec 15, 15:7492-7501.
62. Yokota T., Ura T., Shibata N., et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011 Mar 1, 104:856-862.
63. Tran B., Kopetz S., Tie J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011, epub ahead of print.
64. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007 Oct 22, 97:1139-1145.
65. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009 Jan, 20:84-90.
66. Hawkes E., Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 2010 Oct 1, 28:e529-e531. author reply e32-e33.
67. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010 Mar 1, 28:1254-1261.
68. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009 Mar 20, 27:1477-1484.
69. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009 Mar 1, 69:1851-1857.
70. Prenen H., De Schutter J., Jacobs B., et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009 May 1, 15:3184-3188.
71. Salazar R., Roepman P., Capella G., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011 Jan 1, 29:17-24.